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With over one billion individuals with obe-
sity expected worldwide by 2030, obesity 
is undoubtedly the most prominent single 
disease of the 21st century and a gateway for 
ill health, increasing the risk of a variety of 
related comorbidities1. Concurrent with the 
obesity epidemic, NAFLD is rapidly becom-
ing the leading cause of chronic hepatitis in 
the Western world; in NAFLD, the histolog-
ical features of steatohepatitis and fibrosis 
are associated with an increased risk of pro-
gression to end-stage liver disease (ESLD), 
hepatocellular carcinoma (HCC) and indi-
cation for liver transplantation2,3. Over the 
past few decades, obesity has shifted towards 
an onset earlier in life with a dramatic rise in 
occurrence in childhood: from 5.0% in 1960 
to 16.9% in 2009–2010 (REF. 4). This finding 
represents a serious threat to the health state 
of our children and raises the issue as how 
this earlier advent of overweight will affect 
the burden and management of NAFLD later 
in life. The study by Hagström et al.5 gives a 
meaningful insight on this issue (BOX 1). The 
researchers evaluated a general population 
cohort of 44,248 men aged 18–20 years that 
attended an outpatient visit for conscription 
into military service in Sweden between 1969 
and 1970 and tested the association of basal 
BMI on liver-related morbidity and mor-
tality based on hard, statistically significant 
end points such as the development of ESLD, 
low in this late 1960s cohort compared with 
now. The study did not take into consider-
ation weight trajectories, but early adulthood 
weight-gain seems to carry a higher risk of 
mortality than weight-gain in late adulthood. 
In a large longitudinal Danish study6, a gain 
in BMI between 7 and 13 years of age was 
positively associated with each clinical and 
histological stage of adult NAFLD (steatosis, 
steatohepatitis, fibrosis and cirrhosis) when 
adjusted for initial as well as attained BMI. 
Among children with similar attained BMIs 
at 13 years of age, those who gained in BMI 
had a 16% increased risk of adult cirrhosis per 
1-unit gain in BMI z-score6. Thus, a weight 
gain during school-years is able to induce an 
increased susceptibility of developing NAFLD 
later in life.
Why excessive weight gain in childhood 
seems to influence the entire spectrum 
of liver damage in NAFLD is not known. 
Although childhood and adult obesity are 
correlated, the tracking is generally moder-
ate in magnitude. This finding indicates that 
other mechanisms are also at play. In the 
Cardiovascular Risk in Young Finns Study7, 
the childhood predictors of adult NAFLD at 
follow-up of 31 years were childhood demo-
graphic and metabolic variables (BMI and 
insulin levels), but also non-modifiable risk 
factors, such as male sex, genetic background 
(that is, PNPLA3 and TM6SF2 variants) and 
low birth weight, the latter probably related 
to epigenetic regulation in an adverse intra-
uterine environment. Furthermore, other 
obesity-associated comorbidities, such as 
diabetes mellitus, could have a direct role in 
 promoting liver damage.
cirrhosis, or liver-related death (in National 
Patient and Causes of Death Registries). After 
a follow-up of almost 38 years, 393 patients 
developed ESLD, of which 213 died; basal 
BMI was a strong and independent predic-
tor of ESLD and mortality later in life. Being 
overweight in late adolescence increased the 
risk of liver-related outcomes by 64% com-
pared with a low–normal range BMI and 
each unit increase in BMI increased by 5% 
the  liver-related outcomes5.
This new study definitively establishes that 
the obesity-related risk of future severe liver 
disease starts early in life, though the overall 
effects can be underestimated as the propor-
tion of overweight and obesity was rather 
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A recent study reports that being overweight in late adolescence is 
associated with an increased risk of liver-related morbidity and mortality 
later in life. These findings give further strength to the concerns for the 
deleterious effects of childhood obesity on liver health. Early prevention by 
screening and lifestyle modification should be advised by health policies.
Refers to Hagström, H. et al. Overweight in late adolescence predicts development of severe liver disease later in life: 
a 39 years follow‑up study. J. Hepatol. 65, 363–368 (2016)
Box 1 | Key findings and take-home messages
• NAFLD has gained clinical recognition as main cause of liver disease in children and adults as a 
consequence of the pandemic spread of obesity, particularly in children
• Overweight in late adolescence is associated with an increased risk of liver disease due to NAFLD 
later in life; as a consequence, the threshold of liver-related morbidity and/or mortality is reached 
at a younger age
• Weight gain during school-years carries a higher risk of NAFLD than weight-gain in late adulthood
• High BMI during childhood has been linked to an increased risk of primary liver cancer in adulthood
• Identification of children at risk of future liver disease because of their childhood BMI is advisable 
according to current guidelines on NAFLD
• Prevention of excessive weight gain during childhood and lifestyle modification during early 
adulthood including weight loss should be advised by health policies to reduce the risk of early 
liver disease
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An important piece of information miss-
ing in the report by Hagström et al.5 is the link 
between obesity early in life and the risk of 
HCC arising decades later, but this association 
has already been described. A study8 includ-
ing schoolchildren in Copenhagen showed 
that each unit increase in BMI z-score, at 
every age from 7 through 13 years, increased 
by 20–30% the risk of liver cancer 30 years 
later. To put this in perspective, compared 
with an average height and weight 13-year-old 
boy, a boy of similar height but who weighed 
6 kg more would have a 30% increased risk of 
liver cancer. Similarly, a US study has shown 
that a prior history of obesity in early adult-
hood was more common in HCC cases than 
in matched controls (no obesity onset in early 
adulthood)9. Obesity in the mid-twenties age 
bracket hastened by 4 years the occurrence of 
HCC, whereas obesity in the mid-thirties age 
bracket was associated with a diagnosis of HCC 
5 years earlier.
The findings by Hagström et al.5 have both 
clinical and socioeconomic implications. In this 
population, ESLD due to severe liver disease 
occurred ~45 years of age, which is an exceed-
ingly early occurrence as NAFLD progresses 
slowly and cirrhosis is unusual in young indi-
viduals3. From the clinical point of view, this 
finding means that when overweight and obe-
sity are present since adolescence, the thresh-
old of liver-related morbidity and/or mortality 
due to NAFLD is reached at a fairly young age. 
Most importantly, NAFLD and its complica-
tions are more likely to be anticipated in later 
life when obesity is present since childhood: in 
essence, the timeframe for injury to the liver 
is shifted forward but other factors that might 
have a role need to be clarified [Au: addition 
OK?]. This aspect will unavoidably lead into a 
remarkable reduction of life expectancy and a 
substantial additional societal burden.
How do these findings translate into clin-
ical practice? Importantly, the deleterious 
effects of obesity on liver health should not 
be overlooked, particularly during childhood. 
Children are the most vulnerable population 
and deserve a careful evaluation according 
to the European Association for the Study of 
the Liver, European Association for the Study 
of Diabetes and European Association for the 
Study of Obesity joint guidelines on NAFLD10. 
Also, individuals with a long duration of being 
overweight should be screened for liver disease 
according to the same guidelines10 — the earlier 
the onset of obesity plus the longer the dura-
tion, the higher the risk of NAFLD — and they 
should avoid other risk factors for liver disease, 
such as occasional alcohol abuse or potentially 
hepatotoxic drugs. Although waiting for the 
development of an effective drug therapy of 
NAFLD, the guidelines10 include obesity con-
trol as a priority to reduce the burden of liver 
disease in the community. Combined efforts 
by all health-care providers and societal strat-
egies at the population level to control child-
hood and early adulthood obesity should be 
an immediate priority. If we are going to lose 
the battle of halting ‘obesigenic’ lifestyle, the 
expected decrease in the liver disease burden 
achieved with the discovery of effective thera-
pies for viral hepatitis will be rapidly reversed 
by the epidemic of obesity.
M. Marietti and E. Bugianesi are at the Division of 
Gastroenterology, Department of Medical Sciences, 
University of Torino, AOU Citt→ della Salute e della 
Scienza, Corso Dogliotti 14, 10126 Torino, Italy.
Correspondence to E.B. 
elisabetta.bugianesi@unito.it
doi:10.1038/nrgastro.2016.120 
Published online DD Mon 2016
1. Kelly, T., Yang, W., Chen, C. S., Reynolds, K.  
& He, J. Global burden of obesity in 2005 and 
projections to 2030. Int. J. Obes. 32, 1431–1437 
(2008).
2. Yki-Järvinen, H. Non-alcoholic fatty liver disease  
as a cause and a consequence of metabolic 
syndrome. Lancet Diabetes Endocrinol. 2, 901–910 
(2014).
3. Bhala, N., Jouness, R. I. & Bugianesi, E. 
Epidemiology and natural history of patients with 
NAFLD. Curr. Pharm. Des. 19, 5169–5176 (2013).
4. Ogden, C. L., Carroll, M. D., Kit, B. K. & 
Flegal, K. M. Prevalence of obesity and trends 
in body mass index among US children and 
adolescents, 1999–2010. JAMA 307, 483–490 
(2012).
5. Hagström, H., Stål, P., Hultcrantz, R., Hemmingsson, T. 
& Andreasson, A. Overweight in late adolescence 
predicts development of severe liver disease later 
in life: a 39 years follow-up study. J. Hepatol. 65, 
363–368 (2016).
6. Zimmermann, E. et al. Body mass index in school-
aged children and the risk of routinely diagnosed 
non-alcoholic fatty liver disease in adulthood: a 
prospective study based on the Copenhagen School 
Health Records Register. BMJ Open 5, e006998 
(2015).
7. Suomela, E. et al. Childhood predictors of adult 
fatty liver. The Cardiovascular Risk Young Finns Study. 
J. Hepatol. http://dx.doi.org/10.1016/j.
jhep.2016.05.020 (2016).
8. Berentzen, T. L., Gamborg, M., Holst, C., 
Sorensen, T. I. & Baker, J. L. Body mass index in 
childhood and adult risk of primary liver cancer. 
J. Hepatol. 60, 325–330 (2014).
9. Hassan, M. M. et al. Obesity early in adulthood 
increases risk but does not affect outcomes of 
hepatocellular carcinoma. Gastroenterology 149, 
119–129 (2015).
10. European Association for the Study of the Liver, 
European Association for the Study of Diabetes, 
European Association for the Study of Obesity. 
EASL-EASD-EASO Clinical Practice Guidelines for the 
management of non-alcoholic fatty liver disease. 
J. Hepatol. 64, 1388–1402 (2016).
Competing interests statement
The authors declare no competing interests.
…NAFLD is rapidly 
becoming the leading cause of 
chronic hepatitis in the Western 
world…
NATURE REVIEWS | GASTROENTEROLOGY & HEPATOLOGY  www.nature.com/nrgastro
N E W S  &  V I E W S
Author biographies
Elisabetta Bugianesi is a Professor of Gastroenterology at the University 
of Torino, Italy. She is a world-renowned specialist of NAFLD and her 
research contributed to identify mechanisms of liver damage and 
related complications. She has published >150 papers with >11,000 
citations, and has an h-index of 44.
Milena Marietti is a lecturer of Gastroenterology at the University of 
Torino, Italy. She is part of the research group led by Prof. Bugianesi 
and is actively involved in clinical investigation of NAFLD.
Subject ontology terms
Health sciences / Gastroenterology / Hepatology / Liver diseases / 
Non-alcoholic fatty liver disease [URI /692/4020/4021/1607/2750]
Health sciences / Diseases / Nutrition disorders / Obesity [URI 
/692/699/1702/393]
Health sciences / Risk factors [URI /692/499]
Health sciences / Health care / Disease prevention / Preventive medi-
cine [URI /692/700/459/1748]
O N L I N E  O N LY
